


FORM PTO-1449/A and B (Modified)		APPLICATION NO.: Not yet assigned	ATTY. DOCKET NO.: H00646.70001 US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 25, 2003	
		APPLICANT: Stephen R. Hanson	
		GROUP ART UNIT: Not yet assigned	EXAMINER: Not yet assigned
Sheet	1	of	4

### U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYY
		Number	Kind Code		
	*A1	3,932,407		Beverung, Jr., et al.	01/13/76
	*A2	3,978,213		Lapinet, et al.	08/31/76
	*A3	4,088,753		Parmer	05/09/78
	*A4	4,146,718		Jenks, et al.	03/27/79
	*A5	4,206,214		Harker, et al.	06/03/80
	*A6	4,208,521		Crenshaw, et al.	06/17/80
	*A7	4,357,330		Fleming, Jr., et al.	02/02/82
	*A8	4,393,063		Moncada	07/12/83
	*A9	4,404,212		Moncada	09/13/83
	*A10	4,406,904		Welle, et al.	09/27/83
	*A11	4,432,980		Fleming, Jr., et al.	02/21/84
	*A12	4,436,934		Larock	03/13/84
	*A13	4,444,777		Fleming, Jr., et al.	04/24/84
	*A14	4,568,676		Smith	02/04/86
	*A15	4,743,445		Delwiche, et al.	05/10/88
	*A16	4,847,276		Yarrington	07/11/89
	*A17	5,185,323		Gewirtz	02/09/93
	*A18	5,306,709		Gewirtz	04/26/94
	*A19	5,391,557		Cullinan, et al.	02/21/95
	*A20	5,391,737		Reiter, et al.	02/21/95
	*A21	5,440,020		Coller	08/08/95
	*A22	5,472,944		Gewirtz, et al.	12/05/95
	*A23	5,620,960		Arnold, et al.	04/15/97
	*A24	5,789,539		Daly, et al.	08/04/98
	*A25	5,801,245		Lang	09/01/98
	*A26	6,008,232		Lakshmanan	12/28/99
	*A27	6,043,260		Chen, et al.	03/28/00
	*A28	6,103,740		Lakshmanan	08/15/00
	*A29	6,110,471		Conti, et al.	08/29/00
	*A30	6,156,753		Doherty, Jr., et al.	12/05/00
	*A31	6,287,599	B1	Burnside et al.	09/11/01
	*A32	RE 31,617		Beverung, Jr., et al.	06/26/84
	A33	6,376,242		Hanson	04/23/02

### FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	*B1	EP	0 260 527	A		03/23/88	Abstract
	*B2	EP	0 778 258			06/97	
	*B3	EP	0 994 114			04/00	

*B4	EP	0 514 917		11/25/92	
*B5	EP	0 904 783		03/99	
*B6	HU	206 496	B	11/30/92	Abstract
*B7	PCT	WO99/08524		02/99	
*B8	PCT	WO99/08525		02/99	
*B9	PCT	WO99/20223		04/99	
*B10	PCT	WO93/23426		25/11/93	Abstract
*B11	PCT	WO99/34792		07/15/99	
*B12	UK	GB2,256,195		12/92	

not  
Patented

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*C1	Al-Jibouri, L.M. and Najim, R.A., "Effect of dipyridamole on blood glucose and liver cyclic AMP levels and platelet count during endotoxaemia in mice", <i>Clin. Exp. Pharmacol. Physiol.</i> , 15(7):527-32 (1988) <b>ABSTRACT</b>	
	*C2	Andes, et al., "Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers", <i>Thromb Haemost.</i> , 52(3):325-8 (1984)	
	*C3	Balan, K.K and Critchley, M., "Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32—a 15 year review", <i>Br. J. Radiol.</i> , 70(839):1169-73 (1997) <b>ABSTRACT</b>	
	*C4	Balduini, et al., "Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders", <i>Haematologica</i> , 77(1):40-3 (1992) <b>ABSTRACT</b>	
	*C5	Barnathan, et al., "Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty", <i>Circulation</i> , 76(1):125-134 (1987)	
	*C6	Bellucci, et al., "Positive and negative regulation of megakaryocytopoiesis", <i>C.R. Seances Soc. Biol. Fil.</i> , 190(5-6):515-32 (1996) <b>ABSTRACT</b>	
	*C7	Bunn, H.F., "Pathophysiology of the anemias", <i>Harrison's Principles of Internal Medicine: Hematology and Oncology</i> , 1514, 1566-67 New York, McGraw-Hill, (1991)	
	*C8	Cazenave, J.P. and Gachet, C., "Anti-platelet drugs: do they affect megakaryocytes?", <i>Baillieres Clin Haematol</i> , 10(1):163-80 (1997)	
	*C9	Chen, et al., "Thrombospondin, a negative modulator of megakaryocytopoiesis", <i>J. Lab. Clin. Med.</i> , 129(2):231-8 (1997) <b>ABSTRACT</b>	
	*C10	Cortelazzo, et al., "Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis", <i>N. Engl. J. Med.</i> , 332(17):1132-6 (1995) <b>ABSTRACT</b>	
	*C11	Dale, et al., "Chronic thrombocytopenia is induced in dogs by development of cross-reacting antibodies to the MpL ligand", <i>Blood</i> , 90(9):3456-3461 (1997)	
	*C12	Davies, et al., "Adverse events reported by postmenopausal women in controlled trials with raloxifene", <i>Obstetrics &amp; Gynecology</i> , 93(4):558-565 (1999)	
	*C13	De Serres, et al., "Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits:evaluation of the potential for thrombopoietin neutralizing antibody production in man", <i>Stem Cells</i> , 17:203-209 (1999)	
	*C14	Deng, et al., "A monoclonal antibody cross-reactive with human platelets, megakaryocytes, and common acute lymphocytic leukemia cells", <i>Blood</i> , 61(4):759-764 (1983)	
	*C15	Gaver, et al., "Disposition of anagrelide, an inhibitor of platelet aggregation", <i>Clin. Pharmacol. Ther.</i> , 29(3):381-6 (1981) <b>ABSTRACT</b>	
	*C16	Gewirtz, et al., "Cell-mediated suppression of megakaryocytopoiesis in acquired megakaryocytic thrombocytopenic purpura", <i>Blood</i> , 68(3):619-26 (1986) <b>ABSTRACT</b>	
	*C17	Glushkov, et al., "Changes in hemostatic system indices during hemosorption in healthy dogs", <i>Biull Eksp Biol. Med.</i> , 94(7):95-8 (1982) <b>ABSTRACT</b>	
	*C18	Goldberg, et al., "Thrombocytotic suppression of megakaryocyte production from stem cells", <i>Blood</i> , 49(1):59-69 (1977) <b>ABSTRACT</b>	
	*C19	Gugliotta, et al., "In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia", <i>Br. J. Haematol.</i> , 71(2):177-81 (1989) <b>ABSTRACT</b>	
	*C20	Herron, et al., "Inhibition of megakaryocytic colonies <i>in vitro</i> by anagrelide", <i>Clin. Res.</i> , 34(2):459A (1986) <b>ABSTRACT</b>	
	*C21	Hung, et al., "Focused antithrombotic therapy: novel anti-platelet salicylates with reduced	

not  
Patented

	ulcerogenic potential and higher first-pass detoxification than aspirin in rats", <i>J. Lab. Clin. Med.</i> , 132(6):469-77 (1998) <b>ABSTRACT</b>		
*C22	Jones, et al., "Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide", <i>J. Med. Chem.</i> , 30(2):295-303 (1987) <b>ABSTRACT</b>		
*C23	Lecomte-Raclet, et al., "New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides", <i>Blood</i> , 91(8):2772-80 (1998) <b>ABSTRACT</b>		
*C24	Ludwig, et al., "Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders", <i>Cancer Immunol. Immunother.</i> , 25(3):266-73 (1987) <b>ABSTRACT</b>		
*C25	Mazur, et al., "Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans", <i>Blood</i> , 79(8):1931-1937 (1992)		
*C26	Mazzuconi, et al., "Pipobroman therapy of essential thrombocythemia", <i>Scand J. Haematol.</i> , 37(4):306-9 (1986) <b>ABSTRACT</b>		
*C27	Mazzuconi, et al., "Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results", <i>Haematologica</i> , 77(4):315-7 (1992) <b>ABSTRACT</b>		
*C28	McCune, et al., "Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations", <i>Pharmacotherapy</i> , 17(4):822-6 (1997) <b>ABSTRACT</b>		
*C29	Meanwell, et al., "Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains", <i>J. Med. Chem.</i> , 35(14):2672-87 (1992) <b>ABSTRACT</b>		
*C30	Nagae, S. and Hori, Y., "Immune thrombocytopenia due to Tranilast (Rizaben): detection of drug-dependent platelet-associated IgG", <i>J. Dermatol.</i> , 25(11):706-9 (1998)		
*C31	Negrev, et al., "Influence of nonselective beta-adrenergic impacts on the effects of thrombocytopoietin in mice", <i>Acta Physiologica et Pharmacologica Bulgaria</i> , 13:1:35-39 (1987)		
*C32	Ramires, et al., "Effect of ticlopidine and dipyridamole on platelet aggregation and count in patients with chronic stable angina pectoris", <i>Arq Bras. Cardiol.</i> , 56(4):323-7 (1991) <b>ABSTRACT</b>		
*C33	Robak, T, et al., "Anagrelide—new antiplatelet drug", <i>Acta Haematol Pol.</i> , 25(4):309-15 (1994) <b>ABSTRACT</b>		
*C34	Sato, et al., "Multivariate analysis of risk factors for thrombus formation in University of Tokyo ventricular assist device", <i>J. Thorac Cardiovasc. Surg.</i> , 106:520-7 (1993)		
*C35	Scott, et al., "Local delivery of an antithrombin inhibits platelet-dependent thrombosis", <i>Circulation</i> , 90(4):1951-1955 (1994)		
*C36	Seiler, et al., "Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca <sup>++</sup> fluxes", <i>J. Pharmacol Exp. Ther.</i> , 243(2):767-74 (1987) <b>ABSTRACT</b>		
*C37	Shinagawa, et al., "Allopurinol induced pancytopenia in a patient with myeloproliferative disorder", <i>Rinsho Ketsu</i> , 38(1):64-71 (1997) <b>ABSTRACT</b>		
*C38	Smith, J.B. "Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase", <i>Thromb Res.</i> , 15:28(4):477-85 (1982) <b>ABSTRACT</b>		
*C39	Solberg, et al., "The effects of anagrelide on human megakaryocytopoiesis", <i>Br. J. Haematol.</i> , 99(1):174-80 (1997) <b>ABSTRACT</b>		
*C40	Thaulow, et al., "Blood platelet count and function are related to total and cardiovascular death in apparently healthy men", <i>Circulation</i> 84(2):613-617 (1991)		
*C41	Trowbridge, et al., "Platelet production in myocardial infarction and sudden cardiac death", <i>Thromb. Haemost.</i> , 52(2):167-171 (1984)		
*C42	Van de Pette, "Primary thrombocythaemia treated with busulphan", <i>Br. J. Haematol.</i> , 62(2):229-37 (1986) <b>ABSTRACT</b>		
*C43	van der Loo, et al., "Megakaryocytes and platelets in vascular disease", <i>Bailliere's Clinical Haematology</i> , 10(1):109-123 (1997)		
*C44	Yenuti, et al., "Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline", <i>J. Med. Chem.</i> , 31(11):2136-45 (1988) <b>ABSTRACT</b>		
*C45	Wada, et al., "Characterization of the truncated thrombopoietin variants", <i>Biochem. Biophys. Res. Comm.</i> , 213(3):1091-1098 (1995)		
*C46	Wadenvik, et al., "The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia", <i>Blood</i> , 77(10):2103-8 (1991) <b>ABSTRACT</b>		
*C47	Wilhelmsen, L., "Thrombocytes and coronary heart disease", <i>Circulation</i> 84(2):936-938 (1991)		
*C48	Yataganas, et al., "alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis", <i>Eur. J. Cancer</i> , 27 Suppl 4:S69-71 (1991) <b>ABSTRACT</b>		
*C49	Yeager, et al., "Effects of cyclophosphamide on murine bone marrow and splenic megakaryocyte-CFC, granulocyte-macrophage-CFC, and peripheral blood cell levels", <i>J. Cell.</i>		


		<i>Physiol.</i> , 112(2):222-8 (1982) ABSTRACT		
	*C50	Harker, et al., "Regulation of Platelet Production and Function by Megakaryocyte Growth and Development Factor in Nonhuman Primates", <i>Blood</i> , Vol. 87, No. 5, pp. 1833-1844, (1996)		
	*C51	Harker, "Platelets in Thrombotic Disorders: Quantitative and Qualitative Platelet Disorders Predisposing to Arterial Thrombosis", <i>Seminars in Hematology</i> , Vol. 35, No. 3, pp. 241-252, (1998)		
	*C52	van der Loo, et al. "A Role for Changes in Platelet Production in the Cause of Acute Coronary Syndromes", <i>Arterioscler Thromb Vasc Biol.</i> , Vol. 19, pp. 672-679 (1999)		
	*C53	Broudy, et al., "Thrombopoietin Stimulates Colony-Forming Unit-Megakaryocyte Proliferation and Megakaryocyte Maturation Independently of Cytokines that Signal through the gp130 Receptor Subunit," <i>Blood</i> , Vol. 8, No. 6, pp. 2026-2032 (1996)		
	*C54	Luoh, et al., "Role of the Distal Half of the CMPL Intracellular Domain on Control of Platelet Production by Thrombopoietin in Vivo," <i>Mol. Cell. Biol.</i> , Vol. 20, No. 2, pp. 507-515 (2000)		
	*C55	Landolfi, et al., "Aspirin in Polycythemia Vera and Essential Thrombocythemia: Current facts and Perspectives", <i>Leukemia and Lymphoma</i> , 1996, Vol. 22, Suppl. 1, pp. 83-86		
	*C56	Lane, et al., "Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation," <i>Experimental Hematology</i> , 2001, Vol. 29, pp. 1417-1424		
	*C57	Harker, "Platelets in Thrombotic Disorders: Quantitative and Qualitative Platelet Disorders Predisposing to Arterial Thrombosis", <i>Seminars in Hematology</i> , Vol. 35, No. 3, pp. 241-252 (1998)		
	*C58	van der Loo, et al., "A Role for Changes in Platelet Production in the Cause of Acute Coronary Syndromes", <i>Arterioscler Thromb Vasc Biol.</i> , Vol. 19, pp. 672-679 (1999)		
	*C60	Hennekens, "Update on aspirin in the treatment and prevention of cardiovascular disease" <i>Am. Heart J.</i> , 137 (4 Pt 2):S9-S13 (1999) Abstract only		
	*C61	Tang, et al. "Inhibition of platelet function by antithrombotic agents which selectively inhibit low-Km cyclic 3',5'-adenosine monophosphate phosphodiesterase", <i>J. Lab. Clin. Med.</i> , 95(2):241-57 (1980)		
	*C62	Fleming, et al., "A Potent New Inhibitor of Platelet Aggregation and Experimental Thrombosis, Anagrelide (BL-4162A)", <i>Throm. Res.</i> , 15(3-4):373-88 (1979)		
	*C63	Merck Research Laboratories, N. J., "the merck manual", 1999, p. 918, column 2, paragraph 4		

EXAMINER 	DATE CONSIDERED 1-12-06
--	----------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/666,223, filed September 21, 2000, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

Sheet 1 of 8

Substitute Form PTO-1446 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>18852-002002/5202B</b>	Application No. <b>10/603,401</b>
		Applicant <b>Stephen R. Hanson</b>	
		Filing Date <b>June 25, 2003</b>	Group Art Unit <b>1615</b>

**List of Patents and Publications for Applicant's Information Disclosure Statement**

(37 CFR §1.98(b))

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2002/0119144	08/29/02	Hanson	424	94.63	04/08/02
	AB	2003/0060630	03/27/03	Lang et al.	544	346	04/25/02
	AC	2004/0028729	02/12/04	Shojaei et al.	424	452	04/29/03
	AD	2004/0062800	04/01/04	Burnside et al.	424	468	12/20/01
	AE	2004/0087035	05/06/04	Hanson	436	514	06/24/03
	AF	3,854,480	12/17/74	Zaffaroni	424	514	06/24/03
	AG	4,105,776	08/08/78	Ondetti et al.	514	423	12/22/76
	AH	4,231,938	11/04/80	Monaghan et al.	549	292	06/15/79
	AI	4,302,386	11/24/81	Stevens	530	322	01/16/80
	AJ	4,316,906	02/23/82	Ondetti et al.	514	422	10/31/80
	AK	4,337,201	06/29/82	Petrillo et al.	548	413	12/04/80
	AL	4,344,949	08/17/82	Hoefle et al.	514	307	02/20/81
	AM	4,346,227	08/24/82	Terahava et al.	560	119	06/05/81
	AN	4,374,829	02/22/83	Harris et al.	514	21	07/17/81
	AO	4,410,520	10/18/83	Wattney	514	212.07	07/19/82
	AP	4,444,784	04/24/84	Hoffman et al.	514	460	12/18/80
	AQ	4,452,775	06/05/84	Kent	424	425	12/03/82
	AR	4,508,729	04/02/85	Vincent et al.	514	419	10/02/81
	AS	4,512,924	04/23/85	Attwood et al.	540	500	05/12/83
	AT	4,587,258	05/06/86	Gold et al.	514	412	07/30/84
	AU	4,675,189	06/23/87	Kent et al.	424	490	02/08/85
	AV	4,739,073	04/19/98	Kathawala	548	406	03/04/85
	AW	4,772,684	09/20/88	Brunck et al.	530	316	02/18/88
	AX	4,780,401	10/25/88	Heusser et al.	424	146.1	03/28/85
	AY	4,816,463	03/28/89	Blankley et al.	514	293	04/07/87
	AZ	4,845,079	07/04/89	Luly et al.	514	18	07/11/88
	BA	4,885,292	12/05/89	Ryono et al.	514	18	06/29/89



Examiner Signature 	Date Considered <b>1-12-06</b>
------------------------	-----------------------------------


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18852-002002/5202B	Application No. 10/603,401
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Stephen R. Hanson	
		Filing Date June 25, 2003	Group Art Unit 1615

(37 CFR §1.98(b))

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	BB	4,894,437	01/16/90	Ten Brink	530	328	06/29/87
	BC	4,897,402	01/30/90	Duggan et al.	514	312	06/29/88
	BD	4,904,646	02/27/90	Karanewsky et al.	514	120	04/18/88
	BE	4,906,624	03/06/90	Chucholowski et al.	514	183	08/02/88
	BF	4,906,657	03/06/90	Roth	514	460	12/21/88
	BG	4,920,109	04/24/90	Onishi et al.	514	171	04/18/88
	BH	4,923,861	05/08/90	Picard et al.	514	227.8	02/07/89
	BI	4,929,620	05/29/90	Chucholowski et al.	514	269	06/01/89
	BJ	4,939,143	07/03/90	Regan et al.	514	326	09/25/89
	BK	4,940,727	07/10/90	Inamine et al.	514	450	10/06/88
	BL	4,940,800	07/10/90	Bertolini et al.	548	304.7	07/27/89
	BM	4,946,860	08/07/90	Morris et al.	514	432	11/03/89
	BN	4,946,864	08/07/90	Prugh et al.	514	460	02/01/88
	BO	4,950,675	08/21/90	Chucholowski	514	336	12/21/88
	BP	4,957,940	09/18/90	Roth	514	557	12/21/89
	BQ	4,963,538	10/16/90	Duggan et al.	514	99	03/13/89
	BR	4,968,693	11/06/90	Joshua et al.	514	460	06/09/89
	BS	4,970,231	11/13/90	Lee et al.	514	292	06/09/89
	BT	4,980,283	12/25/90	Huang et al.	435	71.2	06/02/89
	BU	4,992,429	12/12/91	Ullrich et al.	514	129	08/24/89
	BV	4,994,494	02/19/91	Regan et al.	514	569	12/14/89
	BW	4,996,234	02/26/91	Regan et al.	514	563	12/05/89
	BX	4,997,837	03/05/91	Chucholowski et al.	514	256	10/06/89
	BY	5,001,128	03/19/91	Neuenschwander et al.	514	278	12/15/89
	BZ	5,001,144	03/19/91	Regan et al.	514	436	04/17/90
	CA	5,017,716	05/21/91	Karanewsky et al.	556	405	12/01/89
	CB	5,021,453	06/04/91	Joshua et al.	514	510	06/06/90


Examiner Signature 	Date Considered 1-12-06
---	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18852-002002/5202B	Application No. 10/603,401
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))		Applicant Stephen R. Hanson	
		Filing Date June 25, 2003	Group Art Unit 1615



## U.S. Patent Documents


Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	CC	5,025,000	06/18/91	Karenewsky et al.	514	80	03/02/90
	CD	5,034,512	07/23/91	Hudspeth et al.	530	330	08/03/88
	CE	5,036,053	07/30/91	Himmelsbach et al.	514	19	03/15/89
	CF	5,036,054	07/30/91	Kalfenbronn et al.	514	19	06/06/08
	CG	5,055,466	10/08/91	Weller et al.	514	235.8	12/14/89
	CH	5,063,207	11/05/91	Doherty et al.	514	18	07/24/89
	CI	5,063,208	11/05/91	Rosenberg et al.	514	19	06/29/90
	CJ	5,064,825	11/12/91	Chakravarty et al.	514	221	05/16/90
	CK	5,064,965	11/12/91	Ocain et al.	546	99	11/16/90
	CL	5,066,643	11/19/91	Abeles et al.	514	18	01/18/90
	CM	5,071,837	12/10/91	Doherty et al.	514	18	11/28/90
	CN	5,073,566	12/17/91	Lifer et al.	514	381	11/30/89
	CO	5,075,109	12/24/91	Tice et al.	424	193.1	03/18/88
	CP	5,075,451	12/24/91	Ocain et al.	548	302.7	11/16/90
	CQ	5,081,127	01/14/92	Carini et al.	514	359	03/26/90
	CR	5,081,136	01/14/92	Bertolini et al.	514	359	12/13/90
	CS	5,085,992	02/04/92	Chen et al.	435	119	02/25/91
	CT	5,089,471	02/18/92	Hanson et al.	514	11	10/01/87
	CU	5,091,378	02/25/92	Karnewsky et al.	514	80	04/18/88
	CV	5,091,386	02/25/92	Kessler et al.	514	277	09/22/89
	CW	5,095,006	03/10/92	Bender et al.	514	19	07/13/90
	CX	5,095,119	03/10/92	Ocain et al.	548	303.1	11/16/90
	CY	5,098,924	03/24/92	Poss	514	397	09/15/89
	CZ	5,098,931	03/24/92	Duggan et al.	514	460	09/24/90
	DA	5,102,911	04/07/92	Lee et al.	514	510	07/06/90
	DB	5,104,869	04/14/92	Albright et al.	514	212.03	10/25/90
	DC	5,106,835	04/21/92	Albright et al.	514	18	06/22/90

Examiner Signature 	Date Considered 1-12-06
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18852-002002/5202B	Application No. 10/603,401
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))		Applicant Stephen R. Hanson	
		Filing Date June 25, 2003	Group Art Unit 1615

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	DD	5,112,857	05/12/92	Vickers et al.	514	460	09/04/90
	DE	5,114,937	05/19/92	Hamby et al.	514	238.2	11/28/89
	DF	5,116,835	05/26/92	Ruger et al.	514	218	12/07/89
	DG	5,116,870	05/26/92	Smith et al.	514	548	06/06/90
	DH	5,130,306	07/14/92	Duggan et al.	514	121	06/06/90
	DI	5,132,312	07/21/92	Regan et al.	514	312	11/27/90
	DJ	5,133,974	07/28/92	Paradissis et al.	424	480	01/24/90
	DK	5,135,935	08/04/92	Alberts et al.	514	305	05/17/91
	DL	5,166,171	11/24/92	Jendralla et al.	514	460	04/02/91
	DM	5,182,298	01/26/93	Helms et al.	514	455	03/18/91
	DN	5,196,440	03/23/93	Bertolini et al.	514	339	05/04/90
	DO	5,202,327	04/13/93	Robl	514	256	07/10/91
	DP	5,250,435	10/05/93	Cover et al.	435	256.1	06/04/91
	DQ	5,256,689	10/26/93	Chiang	514	452	10/26/92
	DR	5,260,332	11/09/93	Dufresne	514	452	02/07/92
	DS	5,262,435	11/16/93	Joshua et al.	514	452	02/10/92
	DT	5,273,995	12/28/93	Roth	514	422	02/26/91
	DU	5,276,021	01/04/94	Karnewsky et al.	514	120	12/19/91
	DV	5,283,256	02/01/94	Dufresne et al.	514	452	07/22/92
	DW	5,286,895	02/15/94	Harris et al.	560	60	12/07/92
	DX	5,302,604	04/12/94	Byrne et al.	514	338	10/06/92
	DY	5,317,031	05/31/94	MacConnell et al.	514	452	11/24/92
	DZ	5,356,896	10/18/94	Kabadi et al.	514	256	12/22/92
	EA	5,369,125	11/29/94	Berger et al.	514	452	03/19/93
	EB	5,385,932	01/31/95	Vickers et al.	514	460	02/18/92
	EC	5,407,686	04/18/95	Patel et al.	424	468	01/29/92
	ED	5,474,995	12/12/95	Ducharme et al.	514	241	01/10/94

Examiner Signature 	Date Considered <u>1-12-06</u>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18852-002002/5202B	Application No. 10/603,401
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Stephen R. Hanson	
		Filing Date June 25, 2003	Group Art Unit 1615

(37 CFR §1.98(b))

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>SCD</i>	EE	5,506,107	04/09/96	Cunningham et al.	435	7.21	09/29/93
	EF	5,521,213	05/28/96	Prasit et al.	514	443	08/29/94
	EG	5,536,752	07/16/96	Ducharme et al.	514	602	05/08/95
	EH	5,543,297	08/06/96	Cromlish et al.	435	25	05/06/73
	EI	5,550,142	08/27/96	Ducharme et al.	514	365	05/08/95
	EJ	5,552,422	09/03/96	Gauthier et al.	514	368	01/11/95
	EK	5,572,944	11/12/96	Slikkers et al.	114	343	05/27/94
	EL	5,604,253	02/18/97	Lau et al.	514	415	05/22/95
	EM	5,604,260	02/18/97	Guay et al.	514	605	11/04/93
	EN	5,622,985	04/22/97	Olukotun et al.	514	423	04/19/95
	EO	5,639,780	06/17/97	Lau et al.	514	419	05/22/95
	EP	5,643,933	07/01/97	Talley et al.	514	372	06/02/95
	EQ	5,677,318	10/14/97	Lau	514	361	07/11/96
	ER	5,691,374	11/25/97	Black et al.	514	473	05/18/95
	ES	5,698,584	12/16/97	Black et al.	514	462	10/25/96
	ET	5,710,140	01/20/98	Ducharme et al.	514	91	08/16/96
	EU	5,712,171	01/27/98	Zambias et al.	436	518	01/20/95
	EV	5,733,909	03/31/98	Black et al.	514	238.8	01/21/97
	EW	5,736,152	04/07/98	Dunn	424	426	10/27/95
	EX	5,756,083	05/26/98	Elliott	424	85.1	02/09/96
	EY	5,789,413	08/04/98	Black et al.	514	252.01	01/21/97
	EZ	5,817,700	10/06/98	Dube et al.	514	768	03/11/97
	FA	5,830,647	11/03/98	Eaton et al.	435	6	04/26/95
	FB	5,849,943	12/15/98	Atkinson et al.	560	8	04/07/97
	FC	5,861,419	01/19/99	Dube et al.	514	334	07/11/97
	FD	5,922,742	07/13/99	Black et al.	514	345	04/02/97
<i>SCD</i>	FE	5,925,631	07/20/99	Black et al.	514	183	08/03/98

Examiner Signature <i>Eric S. D...</i>	Date Considered <i>1-12-06</i>
--	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18852-002002/5202B	Application No. 10/603,401
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))		Applicant Stephen R. Hanson	
		Filing Date June 25, 2003	Group Art Unit 1615

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>CLP</i>	FF	5,932,546	08/03/99	Barrett et al.	514	4	10/04/96
	FG	5,969,451	10/19/99	Lyons et al.	310	90.5	12/13/96
	FH	6,008,232	12/28/99	Lakshmanan	514	324	08/04/98
	FI	6,103,740	08/15/00	Lakshmanan	514	324	08/04/98
	FJ	6,287,599	09/11/01	Burnside et al.	424	468	12/20/00
	FK	6,376,242	04/23/02	Hanson	435	334	09/21/00
	FL	6,388,073	05/14/02	Lang et al.	544	250	07/26/00
	FM	6,585,995	07/01/03	Hanson	424	424	09/21/00
	FN	6,653,500	11/25/03	Lang et al.	560	22	04/25/02
	FO	6,811,794	11/02/04	Burnside et al.	424	468	12/20/01



**Foreign Patent Documents or Published Foreign Patent Applications**


Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<i>CLP</i>	FP	0 253 310	10/26/94	EP				
<i>CLP</i>	FQ	00/03746	01/27/00	PCT				
	FR	01/21163	03/29/01	PCT				
	FS	01/21259	03/29/01	PCT				
	FT	95/00501	01/05/95	PCT				
	FU	95/18799	07/13/95	PCT				
	FV	95/18972	07/13/95	PCT				
	FW	96/22529	07/25/96	PCT				
	FX	96/25498	08/22/96	PCT				
	FY	96/40750	12/19/96	PCT				
	FZ	97/28190	08/07/97	PCT				
	GA	99/10494	03/04/99	PCT				
<i>CLP</i>	GB	99/47153	09/23/99	PCT				

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Signature <i>W. J. ...</i>	Date Considered 1-12-06
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18852-002002/5202B	Application No. 10/603,401
List of Patents and Publications for Applicant's Information Disclosure Statement			Applicant Stephen R. Hanson	
			Filing Date June 25, 2003	Group Art Unit 1615
(37 CFR §1.98(b))				
Examiner Initial	Desig. ID	Document		
	GC	Balan et al., "Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32—a 15 year review," Br. J. Radiol. 70:1169-73 (1997)		
	GD	Balduini et al., "Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders," Haematologica 77:40-43 (1992)		
	GE	Besselink et al., "The binding of human blood platelets to fibrinogen-, fibronectin-, and Arg-Gly-Asp-derivatized Sephadex G-10," J. Biomater. Sci. Polym. Edn. 7: 551-562 (1995)		
	GF	Broudy et al., "Thrombopoietin Stimulates Colony-Forming Init-Megakaryocyte Proliferation and Megakaryocyte Maturation Independently of Cytokines that Signal through the gp130 Receptor Subunit," Blood 8(6): 2026-2032 (1996)		
	GG	Chen et al., "Thrombospondin, a negative modulator of megakaryocytopoiesis," J Lab Clin Med 129:231-8 (1997)		
	GH	Cook et al., "The effects of two synthetic glycoprotein II b/III a antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active," Thromb Haemost 70:838-47 (1993)		
	GI	Cortelazzo et al., "Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis," N Engl J Med 332:1132-6 (1995)		
	GJ	Endres et al., "Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase," Proc Natl. Acad Sci USA, 95:8880-8885 (1998)		
	GK	Fleckenstein, A., "History of Calcium Antagonists," Circ. Res. 52(suppl1): I.3-I.16 (1983)		
	GL	Griffith et al., "Endothelin-derived relaxing factor," J. Am. Coll. Cardiol., 12:797-806 (1988)		
	GM	Jones et al., "Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide," J Med Chem 30:295-303 (1987)		
	GN	Ludwig et al., "Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders," Cancer Immunol Immunother 25:266-73 (1987)		
	GO	Mazzucconi et al., "Pipobroman therapy of essential thrombocythemia," Scand J Haematol 37:306-9 (1986)		
	GP	McCall et al., "Calcium entry blocking drugs: mechanisms of action experimental studies and clinical uses," Current Problems in Cardiology, 10: 1-80 (1985)		
	GQ	Meanwell et al., "Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains," J. Med. Chem 35: 2672-87 (1992)		
	GR	Moncada, S and E.A. Higgs, "Endogenous nitric oxide: physiology, pathology and clinical relevance," Eur J Clin Invest, 21:361-374(1991)		
	GS	Nagae, S. and Y. Hori, "Immune thrombocytopenia due to tranilast (Rizaben®): Detection of drug-dependent platelet-associated IgG," The Journal of Dermatology 25:706-709 (1998)		
	GT	Remington: The Science and Practice of Pharmacy, Nineteenth Edition, Volume II, Gennaro, A.R. (Ed.), Eaton, Pennsylvania: Mack Publishing Company, p.963 (1995)		
	GU	Van de Pette et al., "Primary thrombocythaemia treated with busulphan," British Journal of Haematology, 62:229-37 (1986)		
	GV	Wang et al., "Interferon-α directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1," Blood 96(6): 2093-2099 (2000)		
Examiner Signature 		Date Considered 1-12-06		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 18852-002002/5202B		Application No. 10/603,401	
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))				Applicant Stephen R. Hanson			
				Filing Date June 25, 2003		Group Art Unit 1615	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
	GW	Wong et al., "Nonpeptide angiotensin II receptor antagonists. I. Pharmacological characterization of 2- <i>n</i> -butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid, sodium salt (S-8307)," J. Pharmacol. Exp. Ther. 247(1): 1-7 (1988)					
	GX	Yeager et al., "Effects of cyclophosphamide on murine bone marrow and splenic megakaryocyte-CFC, granulocyte-macrophage-CFC, and peripheral blood cell levels," J Cell Physiol 112:222-228 (1982)					

Examiner Signature 	Date Considered <u>1-12-06</u>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	